Literature DB >> 32524009

MANIFESTATIONS OF GLUCAGONOMA SYNDROME.

Mauricio Alvarez, Andres Almanzar, Fabian Sanabria, Gustavo Meneses, Louis Velasquez, Luis Zarate.   

Abstract

OBJECTIVE: Glucagonoma is a rare neuroendocrine tumor of the pancreas. We present the case of a young female patient who presented with the major clinical manifestations of glucagonoma syndrome.
METHODS: The major clinical manifestations of glucagonoma syndrome are described in a 44-year-old, female patient. Beyond glucagonoma, the patient also displayed deep venous thrombosis, depression, diabetes, and necrolytic migratory erythema. We discuss the difficulty of treatment of patients with glucagonoma due to the low prevalence of the disorder, scarcity of medical evidence, lateness of diagnosis with liver metastases in most cases, and poor response to chemotherapy with high rates of relapse after surgery. In this case, pancreatectomy and hepatic lobectomy followed by somatostatin analogue therapy was the chosen treatment strategy.
RESULTS: The clinical findings were pancreatic and hepatic masses, proximal deep venous thrombosis, depression, diabetes, and necrolytic migratory erythema. The patient also had elevated levels of glucagon. Pancreatectomy and right hepatic lobectomy were performed and confirmed the glucagonoma.
CONCLUSION: Our case adds new knowledge about glucagonoma which is important due to the low incidence of the disease and the particular characteristics of the syndrome.
Copyright © 2020 AACE.

Entities:  

Year:  2020        PMID: 32524009      PMCID: PMC7279770          DOI: 10.4158/ACCR-2019-0211

Source DB:  PubMed          Journal:  AACE Clin Case Rep        ISSN: 2376-0605


  16 in total

1.  Symptomatic and Radiological Response to 177Lu-DOTATATE for the Treatment of Functioning Pancreatic Neuroendocrine Tumors.

Authors:  Wouter T Zandee; Tessa Brabander; Anela Blažević; Boen L R Kam; Jaap J M Teunissen; Richard A Feelders; Johannes Hofland; Wouter W de Herder
Journal:  J Clin Endocrinol Metab       Date:  2019-04-01       Impact factor: 5.958

2.  Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.

Authors:  Jonathan Strosberg; Ghassan El-Haddad; Edward Wolin; Andrew Hendifar; James Yao; Beth Chasen; Erik Mittra; Pamela L Kunz; Matthew H Kulke; Heather Jacene; David Bushnell; Thomas M O'Dorisio; Richard P Baum; Harshad R Kulkarni; Martyn Caplin; Rachida Lebtahi; Timothy Hobday; Ebrahim Delpassand; Eric Van Cutsem; Al Benson; Rajaventhan Srirajaskanthan; Marianne Pavel; Jaime Mora; Jordan Berlin; Enrique Grande; Nicholas Reed; Ettore Seregni; Kjell Öberg; Maribel Lopera Sierra; Paola Santoro; Thomas Thevenet; Jack L Erion; Philippe Ruszniewski; Dik Kwekkeboom; Eric Krenning
Journal:  N Engl J Med       Date:  2017-01-12       Impact factor: 91.245

3.  Glucagonoma syndrome: A case report.

Authors:  Jishu Wei; Shibo Lin; Cong Wang; Junli Wu; Zhuyin Qian; Cuncai Dai; Kuirong Jiang; Y I Miao
Journal:  Oncol Lett       Date:  2015-05-27       Impact factor: 2.967

Review 4.  The glucagonoma syndrome and necrolytic migratory erythema: a clinical review.

Authors:  Andre P van Beek; Ellen R M de Haas; Willem A van Vloten; Cees J M Lips; Janine F M Roijers; Marijke R Canninga-van Dijk
Journal:  Eur J Endocrinol       Date:  2004-11       Impact factor: 6.664

5.  Necrolytic migratory erythema and pancreatic glucagonoma.

Authors:  Gerzaín Rodríguez; Elga Vargas; Claudia Abaúnza; Sergio Cáceres
Journal:  Biomedica       Date:  2016-06-03       Impact factor: 0.935

6.  Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.

Authors:  Anja Rinke; Hans-Helge Müller; Carmen Schade-Brittinger; Klaus-Jochen Klose; Peter Barth; Matthias Wied; Christina Mayer; Behnaz Aminossadati; Ulrich-Frank Pape; Michael Bläker; Jan Harder; Christian Arnold; Thomas Gress; Rudolf Arnold
Journal:  J Clin Oncol       Date:  2009-08-24       Impact factor: 44.544

7.  Lanreotide in metastatic enteropancreatic neuroendocrine tumors.

Authors:  Martyn E Caplin; Marianne Pavel; Jarosław B Ćwikła; Alexandria T Phan; Markus Raderer; Eva Sedláčková; Guillaume Cadiot; Edward M Wolin; Jaume Capdevila; Lucy Wall; Guido Rindi; Alison Langley; Séverine Martinez; Joëlle Blumberg; Philippe Ruszniewski
Journal:  N Engl J Med       Date:  2014-07-17       Impact factor: 91.245

Review 8.  Glucagonoma syndrome: a review and update on treatment.

Authors:  A M John; R A Schwartz
Journal:  J Eur Acad Dermatol Venereol       Date:  2016-07-16       Impact factor: 6.166

9.  The glucagonoma syndrome. Clinical and pathologic features in 21 patients.

Authors:  R A Wermers; V Fatourechi; A G Wynne; L K Kvols; R V Lloyd
Journal:  Medicine (Baltimore)       Date:  1996-03       Impact factor: 1.889

10.  Glucagonoma syndrome: a case report with focus on skin disorders.

Authors:  Sheng Fang; Shuang Li; Tao Cai
Journal:  Onco Targets Ther       Date:  2014-08-14       Impact factor: 4.147

View more
  2 in total

1.  A Glucagonoma Presenting as Cerebral Vein Thrombosis and Diabetes.

Authors:  Marina Delli Colli; Bader N Alamri; Laura Palma; Juan Rivera
Journal:  Case Rep Endocrinol       Date:  2022-04-22

Review 2.  Third reported case of rare necrolytic migratory erythema associated with bacteraemia due to severe zinc deficiency after revisional Roux-En-Y gastric bypass: case report and literature review.

Authors:  Yassmin Salaheldin; Walid El Ansari; Esraa Aljaloudi; Wahiba Elhag
Journal:  Eat Weight Disord       Date:  2021-06-01       Impact factor: 4.652

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.